Recent Quotes (30 days)

You have no recent quotes
chg | %

ProMetic Life Sciences Inc.  

(Public, TSE:PLI)   Watch this stock  
Find more results for PLI
2.77
-0.09 (-3.15%)
Jun 27 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.75 - 2.86
52 week 1.39 - 3.62
Open 2.81
Vol / Avg. 1.14M/1.34M
Mkt cap 1.67B
P/E     -
Div/yield     -
EPS -0.08
Shares 603.49M
Beta 1.61
Inst. own     -
Jun 10, 2016
ProMetic Life Sciences Inc at Jefferies Healthcare Conference
May 25, 2016
ProMetic Life Sciences Inc at UBS Global Healthcare Conference
May 12, 2016
Q1 2016 ProMetic Life Sciences Inc Earnings Release
May 11, 2016
ProMetic Life Sciences Inc Annual Shareholders Meeting
Mar 31, 2016
Q4 2015 ProMetic Life Sciences Inc Earnings Call and Phase II/III Clinical Trial Results
Mar 30, 2016
Q4 2015 ProMetic Life Sciences Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -342.22% -231.45%
Operating margin -340.01% -243.29%
EBITD margin - -195.94%
Return on average assets -32.54% -27.12%
Return on average equity -56.70% -55.60%
Employees 276 -
CDP Score - -

Address

440 Armand-Frappier Blvd Suite 300
LAVAL, QC H7V 4B4
Canada
+1-450-7810115 (Phone)
+1-450-7814477 (Fax)

Website links

Description

ProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Officers and directors

Simon Geoffrey Best Independent Chairman of the Board
Age: 58
Pierre Laurin Ph.D. President, Chief Executive Officer, Director
Age: 75
Gregory L. Weaver Chief Financial Officer
Age: 59
Steve J. Burton Chief Executive Officer of ProMetic BioSciences Ltd.
Age: 63
Bruce Pritchard Chief Operating Officer
Patrick Sartore General Counsel, Corporate Secretary
John Moran M.D. Chief Medical Officer, Director
Age: 69
Dwun-Hou Chen Ph.D. Senior Vice President, Product and Asia Pacific Development of ProMetic BioTherapeutics, Inc.
Stefan Clulow Director
Age: 44
Charles Kenworthy Director
Age: 57